Physician profile
Steven Karas
NPI 1245221910
$6,135.49
in general payments reported to CMS, 2019-2025
26 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $567 · 2021: $776 · 2022: $1,394 · 2023: $780 · 2024: $1,400 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853 · Travel and Lodging: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.08 |
| Travel and Lodging | $552.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,169.50 | 2019-2025 | Impella |
| Shockwave Medical, INC | $697.35 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $670.03 | 2024 | Indigo System |
| Boston Scientific Corporation | $466.38 | 2019-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $445.66 | 2019-2025 | Camzyos |
| Pfizer INC. | $371.22 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $266.61 | 2020-2022 | |
| Cvrx, INC. | $253.60 | 2023-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $242.88 | 2019-2023 | Xarelto |
| Amgen INC. | $217.85 | 2019-2023 | Repatha |
| Abbott Laboratories | $175.99 | 2022-2023 | Mini Trek |
| Medtronic, INC. | $159.44 | 2022-2025 | Symplicity G3, Linq II |
| Novartis Pharmaceuticals Corporation | $150.59 | 2019-2023 | |
| Novo Nordisk INC | $148.38 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $129.60 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $112.54 | 2019 | |
| Cardiva Medical, INC. | $89.21 | 2021 | |
| Medtronic Vascular, INC. | $81.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $72.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $61.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.13 | 2022-2023 | |
| Gilead Sciences, INC. | $28.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.05 | 2019-2021 | |
| Edwards Lifesciences Corporation | $24.86 | 2025 | |
| Terumo Medical Corporation | $18.25 | 2020 | |
| Lilly USA, LLC | $15.38 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Karas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.